Literature DB >> 8440771

NGF receptor (p75)-immunoreactivity in the developing primate basal ganglia.

J H Kordower1, E J Mufson.   

Abstract

The distribution of the p75 nerve growth factor receptor (NGFr) was determined within the developing human basal ganglia in specimens between weeks 16 through 40 of gestation, 5 years of age, and adulthood. Although NGFr-immunoreactive neurons were rarely seen in the caudate nucleus, a few such neurons were seen in the putamen between prenatal weeks 16 and 26 of development. At 26 and 40 weeks of gestation, the putamen also displayed NGFr-immunoreactive fibers of putative basal forebrain origin. Some of these fibers coursed through the putamen en route to the cortex while others appeared to remain within the putamen. The external segment of the globus pallidus contained dense collections of NGFr-immunoreactive neurons between 16 and 26 weeks of gestation, whereas the internal segment was devoid of immunoreactive perikarya. A few NGFr-immunoreactive neurons were observed within the globus pallidus at embryonic week 40. The expression of NGFr-immunoreactive neurons within the external segment of the globus pallidus was paralleled by a dense granular NGFr-immunoreactive terminal-like staining pattern within the subthalamic nucleus. This staining pattern was most intense at midgestation (weeks 21-26) and was not observed at 40 weeks of gestation or in adulthood. Interestingly, a similar NGFr-immunoreactive terminal-like pattern was also observed within the monkey subthalamic nucleus at embryonic day 120. These data indicate that NGF receptor mediated mechanisms may underlie developmental processes within the primate basal ganglia. The absence of NGFr-immunoreactive neurons within the caudate nucleus, and the paucity of such neurons in the putamen, suggests that NGF receptors play a limited role in primate neostriatal development. Alternatively, developmental events mediated through NGF receptors may occur prior to embryonic week 16. Furthermore, an NGFr/trophic interaction appears to underlie the development of the pallidal-subthalamic nucleus pathway.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8440771     DOI: 10.1002/cne.903270305

Source DB:  PubMed          Journal:  J Comp Neurol        ISSN: 0021-9967            Impact factor:   3.215


  5 in total

Review 1.  Human motor neuron generation from embryonic stem cells and induced pluripotent stem cells.

Authors:  M Nizzardo; C Simone; M Falcone; F Locatelli; G Riboldi; G P Comi; S Corti
Journal:  Cell Mol Life Sci       Date:  2010-07-29       Impact factor: 9.261

2.  Intravenous administration of a transferrin receptor antibody-nerve growth factor conjugate prevents the degeneration of cholinergic striatal neurons in a model of Huntington disease.

Authors:  J H Kordower; V Charles; R Bayer; R T Bartus; S Putney; L R Walus; P M Friden
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

3.  TrkA-immunoreactive profiles in the central nervous system: colocalization with neurons containing p75 nerve growth factor receptor, choline acetyltransferase, and serotonin.

Authors:  T Sobreviela; D O Clary; L F Reichardt; M M Brandabur; J H Kordower; E J Mufson
Journal:  J Comp Neurol       Date:  1994-12-22       Impact factor: 3.215

4.  The Kampo medicine Yokukansan (YKS) enhances nerve growth factor (NGF)-induced neurite outgrowth in PC12 cells.

Authors:  Kazuki Terada; Yukari Matsushima; Kazuhisa Matsunaga; Jiro Takata; Yoshiharu Karube; Atsushi Ishige; Koji Chiba
Journal:  Bosn J Basic Med Sci       Date:  2018-08-01       Impact factor: 3.363

Review 5.  Small-molecule modulation of neurotrophin receptors: a strategy for the treatment of neurological disease.

Authors:  Frank M Longo; Stephen M Massa
Journal:  Nat Rev Drug Discov       Date:  2013-07       Impact factor: 84.694

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.